CABINET (Alliance A021602)
Cabozantinib tripled the time without progression in neuroendocrine tumours that had outgrown other treatments, leading to a 2025 approval.
pNET cohort: PFS 13.8 vs 4.4 months (HR 0.23); extra-pancreatic cohort: PFS 8.4 vs 3.9 months (HR 0.38). NEJM 2024; FDA approval March 2025. ESMO 2025 subgroup: 81% reduction in progression risk in lung and thymic NETs.
Setting
Previously treated advanced pancreatic (n=95) and extra-pancreatic (n=203) NETs: cabozantinib vs placebo
Phase
Phase 3
Sponsor
Alliance / NCI / Exelixis
Registry
Headline result
PFS HR 0.23 (pNET), 0.38 (epNET).
Reported
2024
Enrolled
298
In plain words
What these results mean for people, not percentages
Progression-free survival (pancreatic NET)primarysurrogate endpoint
- Median 13.8 vs 4.4 months with Cabozantinib compared with Placebo; about 9.4 months longer for half the group.
- A median is a midpoint: half the people did better than this and half did worse, so it is not a prediction for any one person.
- Put another way, the treated group had about 77 percent lower chance of the event at any given time (hazard ratio 0.23, likely range 0.12 to 0.42).
Progression-free survival (extra-pancreatic NET)primarysurrogate endpoint
- Median 8.4 vs 3.9 months with Cabozantinib compared with Placebo; about 4.5 months longer for half the group.
- A median is a midpoint: half the people did better than this and half did worse, so it is not a prediction for any one person.
- Put another way, the treated group had about 62 percent lower chance of the event at any given time (hazard ratio 0.38, likely range 0.25 to 0.59).
Be careful
- This is a surrogate endpoint: it measures the cancer being controlled or absent on scans and tests, which often, but not always, translates into living longer.
- These results apply to the people the trial enrolled: Previously treated advanced pancreatic (n=95) and extra-pancreatic (n=203) NETs: cabozantinib vs placebo. People in a different situation may not see the same effect.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
298 participants enrolled.
Progression-free survival (pancreatic NET)primary
HR 0.23 (0.12–0.42)
Cabozantinib
13.8 mo
Placebo
4.4 mo
Progression-free survival (extra-pancreatic NET)primary
HR 0.38 (0.25–0.59)
Cabozantinib
8.4 mo
Placebo
3.9 mo
| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Progression-free survival (pancreatic NET)primary | Cabozantinib | — | 13.8 months | 0.23 (0.12–0.42) | — | — |
| Placebo | — | 4.4 months | ||||
| Progression-free survival (extra-pancreatic NET)primary | Cabozantinib | — | 8.4 months | 0.38 (0.25–0.59) | — | — |
| Placebo | — | 3.9 months |
Pages like this
not linked directly; found by shared links- CompanyExelixis
Shares Cabozantinib, Neuroendocrine tumours.
- CompanyIpsen
Shares Cabozantinib, Neuroendocrine tumours.
- TargetMET
Shares Cabozantinib, Neuroendocrine tumours.